T1	Treatment 72 95	hormonal contraceptives
T2	Treatment 193 234	hormonal contraceptive vaginal ring (CVR)
T3	Treatment 250 289	nonandrogenic progestin Nestorone (NES)
T4	Treatment 294 311	ethinyl estradiol
T5	Treatment 953 1106	randomized to three cycles of treatment with a CVR delivering NES/EE (150/15 microg/day) or a combined OC providing LNG and EE (150/30 microg per tablet)
T6	Treatment 1108 1198	Each cycle consisted of 21 days of active treatment, followed by 7 days without treatment.
T7	Treatment 1269 1645	blood samples were obtained for determinations of plasma concentrations of angiotensinogen, an estrogen-sensitive hepatic protein, and serum concentrations of sex hormone-binding globulin (SHBG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and estrogen- and androgen-sensitive proteins.
T8	Treatment 3328 3338	NES/EE CVR
T9	Treatment 3347 3356	LNG/EE OC
